SAN Sanofi

Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st

Sanofi Head of Human Resources Roberto Pucci to retire; Company names Caroline Luscombe to take over October 1st

   
Sanofi Head of Human Resources Roberto Pucci to retire;

Company names Caroline Luscombe to take over October 1st




Paris - July 26, 2018
- Roberto Pucci, Head of Human Resources, will retire from Sanofi after more than 9 years of service with the company. He will be succeeded in the post by Caroline Luscombe who joins Sanofi on October 1st 2018. Mr. Pucci will be available to Ms. Luscombe until the end of the year to ensure a smooth transition.



Mr. Pucci joined Sanofi in 2009 as Executive Vice President and Head of Human Resources, and has substantially transformed the human resources function and supported Sanofi through a period that saw considerable change in the company.



"Roberto has been an excellent partner in our journey to reshape the organization to align with Sanofi's evolving business ambitions and a great coach to our team and I wish him all the best in his future",
said Sanofi Chief Executive Officer Olivier Brandicourt, M.D.



Appointment of Caroline Luscombe



Ms. Luscombe will report directly to Dr. Brandicourt and will be a member of the Executive Committee.



"Caroline is a seasoned HR leader who will bring tremendous experience and expertise to Sanofi having worked in various industries and across multiple geographies," said Dr. Brandicourt. "Continuing with the high standards set by Roberto, Caroline will drive the focus on our human capital that is needed in a company of our scope".



Ms. Luscombe was most recently Head of Organization and Human Resources and member of the Executive Committee at LafargeHolcim, based in Zurich, Switzerland. Before joining LafargeHolcim Ms. Luscombe has been for 6 years the Global Head of Human Resources of Syngenta.  She previously held a number of senior HR positions at General Electric (GE) in GE Capital Global Banking, GE Money and GE Healthcare Bio-Sciences.  Before its acquisition by GE, she has been Executive Vice President HR for Medical Diagnostics, Amersham plc.



Ms. Luscombe, who started her career in finance at Arthur Young McClelland Moore and was UK controller and Compensation and Benefits manager for the strategy consultants Bain & Company, holds a bachelor's degree in German from University College, London.





About Sanofi



Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions.



With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



Sanofi, Empowering Life



 


Media Relations Contacts

Jack Cox

Tel.: +33 (0)1 53 77 46 46







Investor Relations Contact

George Grofik

Tel.: +33 (0)1 53 77 45 45





Attachment

EN
26/07/2018

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Sanofi

Dominic Rose ... (+2)
  • Dominic Rose
  • Naresh Chouhan

Intron Health - AI Impact on Pharma - Thematic (20pgs) - Winners/Loser...

Our Big Pharma AI thesis is the result of ~25 interviews with industry execs & >100hrs of research. We show ~10% of OPEX could be saved by AI within a few years & conclude the recent sector rally is wholly justified & could run further. We assess the winners & losers from AI adoption and discuss in detail some of the short, mid & long-term consequences. We evaluate the various AI use cases and quantify the potential benefit they may have. We break down SG&A & R&D activities & show where AI is im...

 PRESS RELEASE

Press Release:  Sanofi’s Board of Directors proposes the appointment o...

Press Release:  Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director Sanofi’s Board of Directors proposes the appointment of Christel Heydemann as an independent director  Paris, March 5, 2026. The Board of Directors of Sanofi has decided to propose, at the next Annual General Meeting of shareholders scheduled for April 29, 2026, the appointment of Christel Heydemann as an independent director, as well as the renewal of the mandates of Christophe Babule and Jean-Paul Kress.  Patrick Kron, independent director and Chairman of the Nomination,...

 PRESS RELEASE

Communiqué de presse : Le Conseil d’administration de Sanofi propose l...

Communiqué de presse : Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante   Le Conseil d’administration de Sanofi propose la nomination de Christel Heydemann en qualité d’administratrice indépendante  Paris, le 5 mars 2026. Le Conseil d’administration de Sanofi a décidé de proposer, dans le cadre de la prochaine Assemblée générale des actionnaires prévue le 29 avril 2026, la nomination de Christel Heydemann en qualité d’administratrice indépendante et le renouvellement des mandats de Christophe Babule et Jean-P...

 PRESS RELEASE

Press Release: Filing of an amendment to the French “Document d’Enregi...

Press Release: Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Filing of an amendment to the French “Document d’Enregistrement Universel” containing the Annual Financial Report Paris, March 4, 2026. Sanofi announces today the filing of an amendment to its “Document d’Enregistrement Universel” containing its Annual Financial Report with the French market regulator Autorité des marchés financiers (AMF). This amendment notably includes additions to the report on corporate governance established in accordance with French law. ...

 PRESS RELEASE

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrem...

Communiqué de presse : Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Dépôt d’un amendement au Document d’Enregistrement Universel 2025, contenant le Rapport Financier Annuel Paris, le 4 mars 2026. Sanofi annonce avoir déposé ce jour un amendement à son Document d’Enregistrement Universel 2025 contenant le Rapport Financier Annuel auprès de l’Autorité des marchés financiers (AMF) en France. Cet amendement intègre notamment des compléments au (i) rapport de gestion et au (ii) rapport sur le gouvernement d’entreprise. Le document pe...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch